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Abstract
Circulating tumor cells (CTCs) have been identified with the potential to serve as suitable biomarkers for tumor stage
and progression, but the availability of effective isolation technique(s) coupledwith detailedmolecular characterization
have been the challenges encountered in making CTCs clinically relevant. For the first time, we combined isolation of
CTCs using the ScreenCell filtration technique with quantitative analysis of CTC telomeres by TeloView. This resulted
in the identification and molecular characterization of different subpopulations of CTCs in the same patient. Three-
dimensional (3D) telomeric analysis was carried out on isolated CTCs of 19 patients that consisted of four different
tumor types, namely, prostate, colon, breast, melanoma, and one lung cancer cell line. With telomeric analysis of the
filter-isolated CTCs, the level of chromosomal instability (CIN) of the CTCs can be determined. Our study shows that
subpopulations of CTCs can be identified on the basis of their 3D telomeric properties.
Translational Oncology (2013) 6, 51–65
Introduction
Circulating tumor cells (CTCs) are cells dispersed into the bloodstream
by both primary and metastatic cancers [1,2]. While some CTCs die in
circulation, others are able to proliferate and invade, thereby forming
metastatic deposits at distant organ sites [3]. The spread of CTCs to dis-
tant sites such as bone, brain, lung, and liver has made cancer manage-
ment difficult despite improved early diagnosis [4]. Evidence exists that
CTCs are detectable even in the earliest stages of cancer [3]; thus, this
potentially permits the use of CTC detection and analysis in the early
diagnosis of cancer. The combination of an efficient isolation technique
and a suitable biomarker, that is uniformly present in all tumor cell
types, to characterize CTCs will permit advances in both cancer research
and the development of personalized medicine for cancer patients.
The very low number of CTCs in the bloodstream, which can be
as low as one CTC in 1 to 10 million peripheral blood mononuclear
cells—or one in a billion blood cells (including erythrocytes), has
made the task of efficiently isolating and quantifying CTCs in the
circulation quite challenging [5,6]. CTCs found in the peripheral
circulation may be distinct representations of the different pheno-
types of cancer cells seen in the primary tumors from which they
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originated. This can be explained due to the fact that a biopsy of the
primary tumor cannot identify each and every phenotypic variant
present in the primary tumor irrespective of the number of biopsy
cores taken.
It is believed that only a small percentage of cancer cells in the
primary tumor develop the ability to disseminate and exhibit meta-
static behavior and also CTCs can evolve further while in circulation.
For example, some of these CTCs may lack tumor initiating capabil-
ities, whereas other cells have undergone epithelial-to-mesenchymal
transition [7]. Despite their heterogeneity and rarity in circulation,
CTCs have been shown to have the potential to enhance cancer
staging, prognosis determination, and eventually personalized manage-
ment of cancer [8]. Thus, the need for a highly efficient isolation tech-
nique and a suitable biomarker, which analyzes CTCs irrespective of
their surface antigen expression which may not be conserved, has to
be met.
Telomeres, found at the terminal ends of eukaryotic chromosomes,
serve to protect chromosomes and preserve their integrity. In verte-
brates, telomeres consist of tandem repeated DNA sequences,
(TTAGGG)n, with an average length of 5 to 15 kbp in humans
[9,10]. Telomere dysfunction has been shown to promote numerical
and structural chromosomal instability (CIN), which is a common
feature in cancer [11]. In normal cells, telomeres are arranged in a
specific nonoverlapping manner in the three-dimensional (3D) space
of the nucleus [12,13]. At interphase, the nuclei of cancer cells exhibit
telomeric aggregates (TAs), aberrant telomeric clusters that are asso-
ciated with an altered 3D telomeric organization in the nuclear space
of cancer cells [14,15]; such clusters of telomeres are independent of
telomerase activity and telomere size [15]. These changes in nuclear
architecture of tumor cells have been associated with CIN and ameasure
of the degree of these alterations depicts the advancement and aggres-
siveness of the tumor at that particular time [16,17]. Previouswork done
by our group showed that alterations in the 3D organization of telo-
meres occur in different cancer types, thus making altered 3D nuclear
telomeric profiles a common feature for assessment ofmany cancer types
[17]. Cancer cell nuclei sometimes also feature elongated telomeres
with the presence of different subpopulations of telomere lengths in
the same nucleus [17,18].
On the basis of the above findings, we postulated that investigat-
ing the 3D nuclear telomere organization of CTCs may be key to
efficiently characterizing the associated cancer into different stages
of aggressiveness, therefore providing better monitoring of disease
progression, prognosis determination, and even post-therapy follow-
up for possible relapse in the future. Previous studies of telomeres
have shown significant differences between normal and tumor cells,
premalignant and malignant cells, and tumor cell subpopulations in
different cancer types like plasmacytoma [15], cervical cancer [17,19],
Burkitt lymphoma [12], head and neck cancer [12], Hodgkin’s lym-
phoma [20], glioblastoma [21], and myelodysplastic syndromes/acute
myeloid leukemias [22].
In this study, we have, for the first time, combined a filtration-
based CTC isolation technology from ScreenCell, which isolates
tumor cells from a simple phlebotomy blood sample by capturing
the CTCs that cannot pass through its pores (7.5 ± 0.36 μm in diam-
eter) [6], and our 3D telomere profiling technology that uses quantita-
tive imaging and software (TeloView) to determine the 3D nuclear
profiles of normal versus tumor cells [22]. The 3D telomeric organiza-
tion of lymphoid and nonlymphoid cancers has been examined in the
past by our laboratory and significant differences were found between
normal, preneoplastic, and tumor cells and between tumor stages [23,24].
In the present study, we have isolated by filtration CTCs from patients
with colon cancer, prostate cancer, breast cancer, and melanoma and
also examined one cultured lung cancer cell line followed by 3D quan-
titative analysis of their telomeric signatures using the TeloView [15].
This combined approach resulted in the identification of CTCs and
detection of CTC subpopulations for each tumor type.
In conclusion, we have, for the first time, characterized CTC
subpopulations in different tumors based on their 3D nuclear telo-
meric profiles, thereby encouraging studies in larger patient cohorts
to determine if the 3D telomeric profiles of CTCs can serve as
surrogate biomarkers.
Materials and Methods
Patients
This research was approved by the Research Ethics Board on
human studies at University of Manitoba (Ethics Reference No.
H2011:336) and in Paris, France [Committees for the Protection of
Persons (CPP) Registration No. ID-RCB 2010-A01148-31]. Ten fil-
tered patient samples and one lung cancer cell line were received from
France. Additional nine prostate cancer samples were obtained from the
Prostate Cancer Centre of CancerCare Manitoba. Patients’ consents
were obtained before enrollment in the study. The patient population
consists of nine prostate cancer, one colon cancer, three breast cancer,
and six melanoma cases and one lung cancer cell line (Table 1).
There was no prior knowledge of the clinical data of the patients
involved to enable an unbiased analysis of the samples. The classifi-
cation of patients into stages of cancer was done blindly on the basis
of the 3D profiles of telomeres observed in their CTCs and was con-
firmed with clinical parameters in post hoc fashion.
CTC Isolation by Filtration
Unlike most isolation techniques, the ScreenCell filtration device
isolates the total CTC population, and not subpopulations, from
3 ml of patients’ blood [6]. This isolation is done by size with the
aid of a microporous membrane filter; therefore, expression levels
and/or absence of cell surface antigens play no role in the separation.
The 19-cm-long device consists of a filtration tank, a filter, and a
detachable nozzle attached to it. This nozzle guides the insertion
of a collection EDTA tube to it to gently vacuum suction the blood
through the filter membrane leaving the CTCs on the membrane
[6]. The 18-μm-thick polycarbonate membrane has circular pores
(7.5 ± 0.36 μm) that are randomly distributed throughout the filter
(1 × 105 pores/cm2) [6]. The filtration process is quick (2–3 minutes),
and it preserves both the CTC morphology and microclusters/
microemboli (Figure 1, B–E ). The filtration method was validated
with spiked tumor cells; when two and five spiked cells per 1 ml of blood
were used, the average number of cells recovered were 1.48 (SD, 0.71)
and 4.56 (SD, 0.71), respectively [6].
Three-dimensional Quantitative Fluorescence
In Situ Hybridization
Quantitative fluorescence in situ hybridization was carried out on
the nuclei of the CTCs captured by the filters according to the pro-
tocol earlier described by our laboratory group [12,15,20,21]. In
brief, the cells on the filters are incubated in 3.7% formaldehyde/
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1× phosphate-buffered saline for 10 minutes followed by a 10-minute
treatment with 50 μg/ml pepsin in 0.01 N HCl. The CTCs are
postfixed to the filters with 3.7% formaldehyde/1× phosphate-buffered
saline for 10 minutes before 8 μl of Cyanine 3 (Cy3)–labeled peptide
nucleic acid probe purchased from DAKO (Glostrup, Denmark) is
applied to them. The coverslipped and rubber cement–sealed filters on
slides then undergo a 3-minute denaturation at 80°C followed by a
2-hour hybridization at 30°C. The CTCs containing filters are washed
twice 15 minutes each in 70% formamide/10 mM Tris (pH 7.4),
subjected to a 5-minute wash in 0.1× SSC at 55°C, then washed twice
5 minutes each in 2× SSC/0.05% Tween 20. Finally, the nuclei are
stained with 50 μl of 0.1 μg/ml 4′,6-diamindino-2 phenylindole
(DAPI), dehydrated in graded concentrations of ethanol, and cover-
slipped with Vectashield (Vector Laboratories, Burlington, Ontario)
reagent ready for imaging.
Three-Dimensional Image Acquisition
Images are acquired using a Zeiss AxioImager Z2 microscope (Carl
Zeiss, Toronto, Ontario), equipped with AxioCam HR B&W camera
and 63×/1.4 oil objective. The microscope is equipped with a Cy3
filter for detection of peptide nucleic acid probe–hybridized telomeres
and a DAPI filter for nuclear DNA detection with AXIOVISION 4.8
software (Carl Zeiss). The Zeiss AxioImager Z2 was programmed to
take 80 stacks of images at x and y = 102 nm and z = 200 nm to
capture the different planes of the CTCs that are observed beside
the pores or slightly in the pores. The same acquisition time was used
to acquire Cy3 images of telomeres from each tumor type for quan-
titative comparison and analysis. The acquisition times used in milli-
seconds were given as follows: melanoma, 1290; colon cancer, 212;
breast cancer, 212; prostate cancer, 546; lung cancer cell line, 173.6.
Thirty interphase nuclei were imaged for analysis; deconvolution of
the images was performed with a constrained iterative algorithm
[25]. The reconstructed 3D images were then exported as .tiff files
into our TeloView program for analysis [25].
TeloView Enabled 3D Image Analyses and
Statistical Considerations
TeloView quantifies the telomere numbers, signal intensity, sizes,
distribution, TAs, and nuclear volume for each sample. A graph of
telomere numbers (y-axis) against signal intensity (x-axis) is plotted
for each sample giving a first overview of the CTC 3D telomere pro-
files and of the presence/absence of subpopulations (Figure 3, A–E ).
In addition, aggregate numbers and nuclear volumes are calculated
and included in the analysis.
Statistical parameters considered for characterizing the CTCs in
each patient sample into subpopulations are given as follows: 1) per-
centage of cells with aggregates (PCA), 2) average number of telo-
meres per cell (ANTC), 3) average number of aggregates per cell
(ANAC), and 4) average nuclear volume (ANV).
Nested factorial analysis of variance was used to analyze the
parameters above.
Results
This study was designed to adequately characterize CTCs and poten-
tial subpopulations of CTCs in different cancer types using aberra-
tions in the 3D architecture of telomeres due to telomere dysfunction
as a common biomarker of CIN and a potential surrogate of tumorTa
bl
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aggressiveness. CTCs of prostate, colon, breast, melanoma, and nuclei
of a cultured lung cancer cell line were analyzed and at least two
distinguishable subpopulation patterns were seen in each patient
sample in all of the tumor types (Figures 2 and 3).
The telomeres of five different tumor types were analyzed using
TeloView, which measures the number and size of telomeres and
also identifies the presence of TAs [23,24]. Table 2 shows the differ-
ent parameters computed by the TeloView program such as PCA,
ANTC, ANAC, and ANV. With these data, the degree of telomere
dysfunction can be assessed, thus giving insight into the level of CIN
for each patient. The measurements offer the chance for earlier tumor
detection and better cancer classification. Table 2 shows CTC nuclei
of patient samples MB0189PR, MB0216PR, MB0222PR, COLON
GUI3F, and BRMERT10AA5083PR and nuclei ofH2030 lung cancer
cell line with percentage of cells with TAs greater than 80%, patients
MB0213PR, MB0217PR, COLON GUI5F, BR MIC10AA3956,
BR WUR10AA2499, and BR MIC10AA3934 between 60% and
80%, and the remaining MB0211PR, MB0181PR, MB0182PR,
COLONGUI2F,Mela GOD10AA4991,Mela CAR10AA2213,Mela
SAU 10AA2408, Mela ROB10AA2521, Mela GAU10AA3836, and
Mela CHAN10AA4280 less than 60%. Other important parameters
that vary among the samples are the ANTC and the ANAC. Both the
ANTC and ANAC have corresponding variations among the samples
(Table 2). These data obtained from TeloView can be used to predict
the complexity of genomic instability of the tumors. The TeloView
analysis of CTCs of these five cancer types was done without prior
knowledge of the patients’ clinical data. The deductions and classifica-
tions resulting from the TeloView analysis was then compared with the
clinical data obtained (Table 1).
Morphology of the Filter Captured CTC Nuclei
The distinct 3D nuclear architecture of the CTCs was visualized
through the DAPI filter before image acquisition. The captured
CTCs were found either as solitary or clustered cells scattered around
and sometimes slightly within the pores (Figure 1). In animals, the
importance of CTC clusters and tumor-lymphocyte mixed clusters as
prognostic factors in metastasis process has been mentioned [26,27].
The CTCs are often irregularly shaped (Figures 1 and 2) and larger
than other blood cells enabling their isolation due to their inability
to pass through the filters’ pores (7.5 ± 0.36 μm) [6]; for example,
the prostate cancer cell size ranges between 15 and 25 μm [28].
Figure 1A shows hematoxylin and eosin (H&E)–stained prostate
cancer CTCs (pointed out by arrows) captured by the filter device.
These CTCs are clearly two and three times larger than the pores.
The identities of the cells were confirmed by pathologic examination.
CTCs sometimes display chromatin condensation, unlike most of
the lymphocytes. Solitary lymphocytes mostly pass through the pores
of the filter except in some instances where they are found in
between pores. Lymphocytes sometimes also form lymphocyte-
lymphocyte clusters or lymphocyte-CTC clusters that cannot go
through the pores.
At ×40 microscope magnification, the density of the CTCs present
can be appreciated in each sample with the presence of varying
number of clusters noted. Both the density of the CTCs captured
from 3 ml of each sample and the frequency of the clusters observed
can give a preliminary insight to the status of the disease at the point
when the sample was collected [29]. Figure 1, B–E , shows the isolation
and preservation of CTC clusters in the filtered patients’ blood.
Figure 1. H&E-stained filters with isolated CTCs and CTC clusters
pointed out. (A and B) Filtered prostate and colon cancer CTCs sur-
rounded by pores of the filters. The shapes and sizes of the CTCs
can be acknowledged. (C and E) Clustered breast CTCs and lung
cancer cell line captured by the filter. (D) Melanoma microemboli.
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At ×60 oil magnification, the varying sizes of the CTCs were
observed with associated different chromatin condensation seen.
Further analysis using TeloView measures the nuclear volume and
this distinguishes CTCs from captured clumped lymphocytes that
are smaller in size individually (Table 2). A switch to the Cy3 filter
shows the hybridized telomere signals with varying signal intensity
and numbers that give the first suggestion of different subpopula-
tions within CTCs of the same patient’s filtered blood.
Telomere Numbers and TAs in CTCs
Cancer cells commonly exhibit an altered telomere number per
cell nucleus with the telomeres often being shorter than those in nor-
mal cells. These alterations from the normal cell telomeres have been
attributed to aneuploidy and genomic instability [18].
In this study, Cy3-stained telomeres were analyzed and their signal
intensities evaluated by TeloView. The telomere signal intensity of a
CTC nucleus is dependent on the number of TAs present in that
CTC. This can be projected for the whole sample by calculating
the PCA and the ANAC (Table 2). The program also calculates
the ANTC in each nucleus. The variation in ANTC in the same
sample may be an indication of the presence of CTC subpopulation
and level of tumor aggressiveness [17,21,22]. In Figures 2 to 3, dif-
ferent subpopulations of CTCs in the same patient are shown. The
subpopulations of CTCs are identified on the basis of the differences
in their telomere intensities, which can be due to varying number of
telomeres, size of telomeres, or presence/absence of TAs. TAs are
commonly seen in tumor cells [14,17] (Figure 2, Af, and Cf–Ef
show prominent TAs) and their analyses has been shown to be useful
in tumor characterization [12,17].
Figure 2 shows representative 2D and 3D images of isolated
CTCs. The figure represents different subpopulations of CTCs pres-
ent in the same prostate cancer patient (MB0181PR). In Figure 2,
the nuclear DNA is stained with DAPI (blue) and telomeres (red),
which are within the nuclei, are Cy3 stained. Images in Figure 2, Aa
and Ab, are of a cell that represents the subpopulation with low telo-
mere intensity in this prostate cancer patient evident by the scanty
number of signals observed. The two other CTC subpopulations
represented in the same prostate cancer patient are the medium
(Figure 2, Ac and Ad ) and high (Figure 2, Ae and Af ) telomere inten-
sity CTCs. A similar classification is shown in the colon cancer patient
GUI3F (Figure 2B) with increasing numbers of telomeres seen along
the classes of CTCs but a higher than normal number of telomeres ob-
served in CTCs that belong to the high intensity subpopulation (Fig-
ure 2, Be and Bf ). This irregularly high number of telomeres seen is one
of the features of cancer cells that result from CIN [17]. Figure 2C
shows 2D and 3D images of cells representing subpopulations in a
breast cancer patient: BR MIC10AA3934, with low (Figure 2, Ca
and Cb), medium (Figure 2, Cc and Cd ), and high (Figure 2, Ce
and Cf ) intensity telomere signals. Figure 2D shows subpopulations
in a melanoma patient: Melanoma CAR10AA2213, which is similar
to subpopulations in breast cancer patient (BR MIC10AA3934)
(Figure 2C ) except for the presence of more TAs (Figure 2Df ) in
the melanoma patient. The lung cancer subpopulations in cell line
H2030 are shown in Figure 2E . It was noted that this lung cancer cell
line generally has high telomere numbers, but their telomere sizes vary.
The telomere size was used to group the CTCs into subpopulations
(Figure 2E ).
From the results shown in Figure 2, it is clear that different sub-
populations of CTCs are present in the same cancer patients and
that these subpopulations can be identified by TeloView analysis.
In the same tumor type, the variations in telomere intensities in addi-
tion to the presence and frequency of TAs may, in the future and
with larger patient cohorts, permit the classification of cancer into
stages of progression and aggressiveness with the prospects of improving
cancer management.
Telomere Numbers versus Telomere Intensity
Measured in CTCs
Our analysis tool, the TeloView program [23,24], plots a graph of
telomere length (signal intensity) on the x-axis against the number
of telomeres on the y-axis. The signals with the same intensity fall
on the same spot on the graph and this gives a picture of the distri-
bution of CTC subpopulations within each patient’s filtered blood.
For normal cells, this plot usually has a single peak, which ranges
between 40 and 60 telomeres per nucleus on the y-axis [13]. A direct
comparison of prostate cancer CTCs and lymphocytes from the same
patient (MB0239PR) is shown in Figure W1. Not only are the
numbers of telomeres detected different between CTCs and lympho-
cytes of the same patient but also did we measure a size difference
between the two cell types with average sizes of CTC nuclei being
Figure 2. (A) 2D (Aa, Ac, and Ae) and 3D (Ab, Ad, and Af) images of sample MB0181PR prostate cancer CTCs. At least three different
subpopulations of CTCs were identified and depicted in this patient. Images Aa and Bb show cells with scanty telomeres in contrast to
Ac and Ad, which represent population of CTCs with higher telomere intensity. In images Ae and Af, the cells show the presence of TAs,
thus signal intensities are even higher than seen in Ac and Ad. (B) 2D and 3D representations of different subpopulations in colon cancer
patient sample GUI3F. In the 2D images (Ba, Bc, and Be) the telomere signals are represented by the red dots and the corresponding
signals of all image stacks are shown in the 3D images beside them. There is a graduated increase in signal intensity along the CTC
subpopulations shown in Bb, Bd, and Be, respectively. Image Bb represents the low extreme, whereas image Be shows an extremely
high number of signals with a shorter than normal telomeres, a feature of advanced cancer stage. (C) Representations of three different
subpopulations of CTCs in the same breast cancer patient (Br 3934 MIC) are shown in both 2D and 3D images. The signal intensity
increases from Ca and Cb to Cc and Cd with increased numbers of telomeres. Subpopulation of cells with high number of TAs is rep-
resented by image Cf. (D) 2D and 3D images of melanoma CTCs showing different subpopulations. The nuclear architecture is outlined
in blue by DAPI in the 2D images. Images Da and Db have fewer telomeres; more signals are present in subpopulation represented by
image Dd with few TA formation. The last subpopulation represented here by image Df has many TAs giving it a high signal intensity.
(E) Representative images of lung cancer cell line, which were found to be generally larger than the other tumors examined. All the
subpopulations found in the H2030 lung cancer examined had more than normal number of telomeres. The different subpopulations
are identified using the difference in signal intensities in the nuclei with the low signals represented by images Ea and Eb, medium
intensity by Ec and Ed, and high intensity subpopulation as images Ee and Ef.
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Figure 2. (continued).
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Figure 2. (continued).
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Figure 2. (continued).
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Figure 2. (continued).
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more than three-fold larger than those of the lymphocytes of the
same patient, captured on the same filter (Figure W1).
CTCs of all patients give 3D telomeric profiles with either a very
high number or very low number of telomeres (Figure 3, A–E ). Fig-
ure 3 shows plots of the different representative CTCs’ telomere
numbers against their intensities. Many deviations from the 3D telo-
mere profiles of normal cells [12,13,23] (Figure W1) were observed;
the striking regular finding in the graphs from these CTCs is the
presence of multiple peaks, which represent different subpopulations
in the samples. The plots revealed the different subpopulations of
Figure 3. Telomere numbers against telomere intensities for the five different tumor types (A–E). The uniqueness of the tumor types is
depicted in these plots and the multiple peaks indicate the different subpopulations of telomeres present in the same patient blood
sample. Note that the scales of the graphs are not the same; they were adjusted to give a clear presentation of the subpopulations
observed in each patient sample.
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CTCs in the same patient shown by the red line demarcations in the
graphs. The subpopulations can be identified according to their signal
intensities, i.e., low, medium, and high intensities (Figure 3, A–E ).
Figure 3A is a plot of a prostate patient’s signal intensity against num-
ber of telomeres, the telomere numbers peak at 18 (below the normal
range [12,13,23]), and there are three populations identified by red
line demarcations on the plot, i.e., low, medium, and high intensity
groups (Figure 3, A–E ). The plot for GUI3F (Colon CA) in
Figure 3B is a sharp contrast to Figure 3A with telomere numbers
having a peak at 110 (Figure 3B ). This disparity in different cancer
types should be studied further with larger cohorts of the same cancer
type. Although the plot for BR MIC10AA3934 (Figure 3C ) has a
telomere number peak of 45, it has multiple peaks that signify the
different subpopulations present in the same patient (Figure 3C ).
The zigzag nature of the plot for melanoma gives it a peculiar pattern
(Figure 3D ); it also has its highest telomere number peak at 19 (below
the normal range). Three distinct subpopulations of telomere inten-
sities can be identified in this plot (Figure 3D). The plot for lung
cancer cell line depicts its high telomere number with a peak of telo-
mere numbers at 290, most of which are short telomeres as earlier
shown in 3D images (Figure 2D, images b and d ).
Uniqueness of Telomere Structural Changes in Cancer Types
When analyzing five different cancer types, it was observed that
there might be a characteristic feature in the 3D telomere architec-
tural changes seen in each of these cancer types. Although they all
exhibit the presence of subpopulations of CTCs in the same patient
sample, the telomeres of these cancer cells may tend to have similar
features in each tumor type. The prostate, melanoma, and breast can-
cer CTCs may tend to form high numbers of TAs (Figure 2, Af, Df,
and Cf ). The colon cancer CTCs and lung cancer cell line may tend
to have significantly increased numbers of telomeres (Figure 2, Bf
and Ef ). The peculiarities seen in telomeres of different tumor types
are also exhibited in the plots of their telomere numbers against telo-
mere intensities (Figure 3, A–E ). The architectural alterations seen in
the telomeres seem to be specific to each cancer type.
Frequencies of CTC Subpopulations
Three milliliters of blood per patient captures CTCs present in
this volume of blood and allows for the detection of those CTCs that
are present in that sample. Duplicate and triplicate samples taken at
the same time and from the same patient will result in the isolation of
varying numbers of CTCs due to their rare presence per milliliter
blood. This will also impact on the frequencies of individual sub-
populations detected. We can therefore only conclude that CTC sub-
populations are present, but the frequency of each population may vary
in small sample volumes. Two examples are provided here to illustrate
this point. Patient GUI with colon cancer had three 3-ml blood
samples examined (2F, 3F, and 5F) and their 3D nuclear architecture
analyzed. 2F, 3F, and 5F have telomeres with low intensity at 58.16%,
54.34%, and 64.42%, respectively; medium intensity telomeres were
found at 38.27%, 36.82%, and 33.85%, respectively, and high inten-
sity telomeres had frequencies of 3.57%, 6.99%, and 1.73%, respec-
tively (Table 2). This is a fairly consistent representation of the telomere
intensity subpopulations in three different samples of the patient GUI.
A different example is represented by the breast cancer patient
MIC. Two different samples (10AA3956 and 10AA3934) were
obtained at the same time from the patient, and the 3D nuclear
analysis of the CTCs revealed the presence of three different telomere
subpopulations. 10AA3956 and 10AA3934 had percentages of
telomeres with low intensity of 77.36 and 35.38, medium intensity
of 20.22 and 62.01, and then high intensity of 2.42 and 2.61, respec-
tively (Table 2). The frequency of each population is more variable
(except in the high telomere intensity group) than it was in patient
Table 2. Summary of Data Obtained from 22 CTC Samples of Five Different Cancer Types Analyzed and the Calculated Parameters Used in Characterization of the CTCs.
CTC Sample Percentage of Telomere Intensity
Subpopulations in the Same Patient
PCA ANTC ANAC ANV (μm3) Average Nuclear
Diameter (μm)
Low Medium High
MB0181PR 83.39 14.84 1.77 46.66 9.43 0.5 235.50 7.66
MB0182PR 94.58 0 5.42 37.04 8.88 0.48 294.54 8.25
MB0189PR 38.16 58.74 3.1 82.35 28.44 2.18 1443.89 14.02
MB0211PR 33.61 63.92 2.47 53.33 16.17 0.93 1154.02 13.01
MB0213PR 52.06 45.27 2.67 63.33 16.2 1.267 1062.18 12.66
MB0216PR 71.45 23.36 5.19 86.66 21.83 1.8 1032.66 12.54
MB0217PR 46.94 48.98 3.67 66.66 16.33 1.3 702.76 11.03
MB0222PR 32.17 65.22 2.61 86.66 23 2.367 657.97 10.79
MB0239PR 100 0 0 80 36.4 3.4 211.47 7.39
Colon GUI 2F 58.16 38.27 3.57 26.66 6.53 0.26 212.04 7.40
Colon GUI 3F 54.34 36.82 6.99 83.33 35.3 3.7 633.79 10.66
Colon GUI 5F 64.42 33.85 1.73 66.66 17.33 1.33 485.32 9.75
BR MERT 10AA5083 34.87 58.9 6.23 83.33 22.5 2.03 480.24 9.72
BR MIC 10AA3956 77.36 20.22 2.42 70 24.73 1.73 469.73 9.64
BR WUR 10AA 2499 54.98 39.58 2.44 75 19.19 1.66 413.92 9.25
BR MIC 10AA3934 35.38 62.01 2.61 73.33 17.9 1.66 564.07 10.25
Mela GOD 10AA4991 57.82 12.24 29.93 33.33 9.93 0.66 224.98 7.55
Mela CAR 10AA2213 85.52 37.17 3.36 36.66 13.9 0.46 292.49 8.24
Mela SAU 10AA2408 73.1 24.83 2.07 53.33 9.66 0.76 374.48 8.94
Mela ROB 10AA2521 76.64 21.77 1.13 63.33 14.7 1.1 866.57 11.83
Mela GAU 10AA3836 68.58 29.67 1.75 70 13.36 1.1 420.05 9.29
Mela CHAN 10AA4280 79.31 13.79 6.89 73.33 12.57 1.1 398.80 9.13
Lung CA Cell Line H2030 66.32 32.22 1.46 100 104.057 12.81 1893.97 15.35
PR, prostate cancer; Colon, colon cancer; Br, breast cancer; Mela, melanoma; Lung CA, lung cancer.
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GUI. Therefore, the average of multiple samples obtained at the
same time will only provide confirmation of the presence of distinct
CTC subpopulations in a patient but will not give an absolute dis-
tribution frequency.
Discussion
Our study showed that CTCs isolated from patients with different
cancers including breast, prostate, melanoma, and colon exhibit
unique 3D telomeric profiles. We observe distinct subpopulation
in each CTC/tumor type, based on quantitative analysis of 3D
nuclear telomeric images using TeloView [23]. Our study is a
proof-of-principle analysis that illustrates the feasibility of 3D quan-
titative fluorescence in situ hybridization analysis of CTCs isolated
using a filtration device and the subsequent quantitative analysis of
3D telomeric profiles of CTCs leading to the identification of unique
subgroups of CTCs.
This analysis gives a snapshot of the molecular makeup of a
patient’s tumor cells at a specific point of assessment. It is known
that cancer evolves [30]; therefore, profiling of CTCs using their
telomeres as a potential future biomarker may permit the assessment
of CIN at specific time points of their evolution and natural history
[22]. The 3D profiles of the CTCs of each type of cancer appear
tumor type–specific. To validate the accuracy of telomeric classifica-
tion of cancer progression, a larger cohort of patients with the same
cancer type of varying clinical stages and pathologic grades will need
to be analyzed and validated according to clinical parameters and
treatment outcome.
As previously shown, the 3D telomeric organization is altered
within the nucleus of cancer cells. 3D nuclear architecture of telo-
meres has been used to assess and profile many cancer types, includ-
ing our recent work in the profiling of myelodysplastic syndromes
and acute myeloid leukemias into subgroups using their 3D telomeric
architecture [22]. Other tumors that display alterations in their 3D
telomeric architecture have been studied, including plasmacytoma
[15], cervical cancer [17,19], Burkitt lymphoma [12], head and neck
cancer [12], Hodgkin’s lymphoma [20], and glioblastoma [21]. The
use of telomeric profiling technique on CTCs of cancer patients over
time may help the understanding of cancer evolution/progression
and eventually lead to improvements in cancer management.
The importance of CTCs as possible biomarkers for the analysis of
tumors has been acknowledged, and this explains the many methods
that have been attempted to isolate CTCs in the past. One recent
technique is an assay using an anti–epithelial cell adhesion molecule
(anti-EpCAM) antibody to capture CTCs expressing this antigen on
their surfaces with the CellSearch System [31]. The CTCs must have
>2000 EpCAM molecules on their surfaces for them to be captured
[31]. This method lacks efficiency because of tumor cell hetero-
geneity, low EpCAM expression levels on some CTCs, or EpCAM-
deficient CTCs like melanoma CTCs. In addition, because the
EpCAM expression levels may change as cells become CTCs, many
CTCs will not be captured because they do not express the “adequate”
amount of EpCAM [31,32].
Because of the extremely low number of CTCs [33], reverse
transcription–polymerase chain reaction–based assays have been
previously used to isolate CTCs. The major pitfalls of this method
of CTC isolation were the destruction of the cells’ integrity during
RNA extraction and also the ineffectiveness of reverse transcription–
polymerasechain reaction to distinguish between circulating tumor
and nontumor cells [34,35].
The ScreenCell device we used here makes the analysis of the
entire population of CTCs in a patient’s blood sample possible by
its non–antigen-specific filter isolation technique [6]. With an iso-
lation of the entire population of CTCs dispersed from a solid tumor,
we are equipped with a better representation of the tumor than biopsy
or dissection can offer. The combination of isolation of CTCs by the
ScreenCell device and analysis of 3D architecture of telomeres by Telo-
View permits the identification and characterization of the different
constituent subpopulations of CTCs in the same patient. This combi-
nation of techniques has the potential of providing a suitable surrogate
biomarker for efficient assessment of different types of tumors as dem-
onstrated with the hope that this will, in the future, translate into
improved prognostication abilities and therapeutic planning for differ-
ent tumor types.
In addition, the presence and frequency of circulating tumor micro-
emboli in circulation as shown in Figure 1, B–E , H&E-stained filtered
melanoma blood, can be estimated using the combination of CTC iso-
lation by filtration and 3D analysis of CTCs. These circulating tumor
microemboli can lead to clogging of small blood vessels, thus causing
anemia in the region supplied by the affected vessels [36]. This can
result in increased morbidity and could be included as a prognosticator
that could enhance the classification andmanagement of cancer patients.
Filtration and 3D analysis of CTCs from cancer patients may lead
to early detection of abnormal cells in circulation and this detection
will be followed by extensive diagnostic tests to achieve a possible
lifesaving early diagnosis. Furthermore, response to cancer manage-
ment may be monitored using changes in 3D telomeric profiles of
CTCs and drugs can be designed to target-specific subpopulation(s)
of CTCs that may have been identified to be resistant to an earlier
therapy regimen. In conclusion, our study demonstrates that it is
feasible to isolate and characterize different subpopulations of CTCs
in cancer patients by analyzing their 3D telomeric architectures after
ScreenCell filter isolation.
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Figure W1. Comparison of 3D nuclear telomere profiles of CTCs isolated from prostate cancer patient MB0239PR with lymphocytes
from the same patient captured on the same filter. Green, 3D nuclear telomere profile of CTCs from the patient. Red, 3D nuclear profile
of lymphocytes from the same patient. The average 3D volume of lymphocytes is 211.47 μm3 and the nuclear diameter is 7.39 μm. The
ANV of CTCs of this patient is 665.99 μm3 and the average nuclear diameter is 10.78 μm. The ANV of lymphocytes is 3.15 times smaller
than that of average CTC in this same patient. Note that due to filtration, 10% less telomeric signals are detectable in 3D nuclei in normal
lymphocytes than have been reported by us and others [12,13,23].
